GeminIQ Website Logo

Viewing AMGN free

Subscribe for full history, 50+ metrics, screener, watchlist...

AMGEN INC

AMGN

Companies in Biological Products, (No Diagnostic Substances)

Subscribe to unlock 17+ years of data

Financial Statements

Values in Millions ($)
2026-03-31
2025-12-31
2025-09-30
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Data beyond 3 years is for subscribers only.

Unlock 17+ years of financial data

Start 7-day free trial
Subscriber-only column
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value
12,0389,1299,4458,0288,81011,9739,0119,3019,70810,94434,74134,248
Accounts Receivable Net Current
9,1389,5708,4908,7018,1326,7827,3176,9346,7767,2686,1455,830
Available For Sale Securities Debt Securities Curr…
---------000
Inventory Net
6,1866,2256,3466,5836,7296,9987,3627,9958,7249,5185,0264,978
Other Assets Current
4,1134,1333,6043,4223,2583,2773,0762,9762,8212,6022,5652,324
Assets Current
31,47529,05727,88526,73426,92929,03026,76627,20628,02930,33248,47747,380
Property Plant And Equipment Net
8,2167,9137,2206,8556,6816,5436,1566,0976,0025,9415,5635,532
Intangible Assets Net Excluding Goodwill
21,37922,27623,13924,61425,72427,69928,92030,17231,37232,64113,15014,633
Goodwill
18,67418,68018,67618,67418,64518,63718,65818,61618,57018,62915,50915,531
Other Assets Noncurrent
12,76012,66013,22111,02011,3889,93010,3838,8169,0079,6117,8357,193
Assets
92,50490,58690,14187,89789,36791,83990,88390,90792,98097,15490,53490,269
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current
2,9352,3672,8383,0102,4061,9082,1472,2671,6281,5901,3581,212
Accrued Liabilities Current
16,58318,52316,80015,02217,23417,64114,62113,72214,12715,35914,16813,718
Long Term Debt Current
5,4374,5992,1532,4443,3683,5503,5445,5283,9591,4431,4282,167
Liabilities Current
24,95525,48921,79120,47623,00823,09920,31221,51719,71418,39216,95417,097
Long Term Debt Noncurrent
51,88650,00552,43453,76054,01356,54956,85457,11760,06163,17059,04059,377
Deferred Income Tax Liabilities Net
1,3441,3661,4581,3861,5101,6161,7111,7801,8622,354--
Liability For Uncertain Tax Positions Noncurrent
2,7642,6902,6162,5112,4192,3492,2802,2053,9644,6804,5794,478
Other Liabilities Noncurrent
2,3652,3782,2232,3362,2102,3492,1992,3632,3572,3262,3052,536
Stockholders Equity
Common Stocks Including Additional Paid In Capital
34,03034,02333,84133,68033,57833,53333,39333,20433,08233,07032,75332,601
Retained Earnings Accumulated Deficit
-24,650-25,107-23,800-25,708-27,140-27,590-25,530-27,124-27,870-26,549-24,971-25,540
Accumulated Other Comprehensive Income Loss Net Of…
-190-258-422-544-231-66-336-155-190-289-126-280
Stockholders Equity
9,1908,6589,6197,4286,2075,8777,5275,9255,0226,2327,6566,781
Liabilities And Stockholders Equity
92,50490,58690,14187,89789,36791,83990,88390,90792,98097,15490,53490,269
Common Stock Par Or Stated Value Per Share
000000000000
Common Stock Shares Authorized
2,7502,7502,7502,7502,7502,7502,7502,7502,7502,7502,7502,750
Shares Outstanding
540539539538538537538537536535535535

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Custom Table

0/5
Search a metric to start building a table

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Interactive Financial Visualizations

0/1
Search a metric to start building a visual

Subscribe to unlock 17+ years of data

Earnings Market Reaction

Fiscal Year
Q1 1 Month
Q1 2 Month
Q1 3 Month
Q2 1 Month
Q2 2 Month
Q2 3 Month
Q3 1 Month
Q3 2 Month
Q3 3 Month
Q4 1 Month
Q4 2 Month
Q4 3 Month
20263.65%3.13%11.90%---------
2025-2.55%3.79%5.74%1.89%-3.33%3.32%8.77%4.83%8.55%0.09%-5.76%-10.66%
2024-1.05%-0.30%7.18%7.57%3.97%2.14%-7.27%-17.08%-14.33%11.57%1.11%-3.41%
2023---6.24%10.93%15.53%4.63%12.00%21.33%-4.89%-6.21%8.15%

Data beyond 3 years is for subscribers only.

Unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data and 50+ calculated metrics

Performance and Valuation Metrics

Metrics
2026-03-31
2025-12-31
2025-09-30
2025-06-30
2025-03-31
2024-12-31
2024-09-30
2024-06-30
2024-03-31
2023-12-31
2023-09-30
2023-06-30
Subscriber-only columnSubscriber-only columnSubscriber-only columnSubscriber-only column

Data beyond 3 years is for subscribers only.

Unlock 17+ years of financial data

Start 7-day free trial
Subscriber-only column
Liquidity Ratios
Current Ratio
1.26
1.14
1.28
1.31
1.17
1.26
1.32
1.26
1.42
1.65
2.86
2.77
Quick Ratio
1.01
0.90
0.99
0.98
0.88
0.95
0.96
0.89
0.98
1.13
2.56
2.48
Working Capital
6.52B
3.57B
6.09B
6.26B
3.92B
5.93B
6.45B
5.69B
8.32B
11.94B
31.52B
30.28B
Leverage & Debt
Debt to Equity
2.72
2.94
2.27
2.76
3.71
3.93
2.70
3.63
3.93
2.95
2.21
2.52
Interest Coverage TTM
3.93
3.30
3.04
2.79
2.44
2.30
1.93
1.93
2.21
2.75
3.59
4.57
Debt Ratio
0.27
0.28
0.24
0.23
0.26
0.25
0.22
0.24
0.21
0.19
0.19
0.19
Efficiency & Turnover
Asset Turnover TTM
0.41
0.40
0.40
0.39
0.37
0.35
0.36
0.34
0.33
0.35
0.35
0.36
Days Sales Outstanding TTM
84.68
81.20
80.20
81.72
79.73
76.72
75.52
75.30
77.32
83.07
78.02
76.60
Receivables Turnover TTM
4.31
4.49
4.55
4.47
4.58
4.76
4.83
4.85
4.72
4.39
4.68
4.77
Per Share Metrics
Diluted EPS TTM
14.34
14.23
12.92
12.23
10.97
7.56
7.80
5.79
7.02
12.49
14.06
14.86
Free Cash Flow Per Share TTM
15.92
15.06
21.45
19.71
20.29
19.36
11.70
10.21
13.24
13.76
17.53
18.10
Dividend Per Share TTM
9.64
9.52
9.38
9.25
9.11
9.00
8.88
8.75
8.63
8.52
8.33
8.14
Margin Metrics
Gross Profit Margin TTM
68.26%
67.25%
66.16%
64.48%
63.00%
61.53%
60.48%
63.30%
66.37%
70.02%
73.59%
74.16%
Operating Profit Margin TTM
28.39%
24.71%
24.11%
23.46%
21.82%
21.71%
19.11%
20.02%
23.59%
28.01%
33.00%
35.72%
Net Profit Margin TTM
20.96%
20.98%
19.47%
18.96%
17.39%
12.24%
13.00%
10.12%
12.74%
23.83%
28.20%
30.02%
Growth Metrics
Net Revenue Growth (1Y)
9.07%
9.95%
10.56%
12.88%
15.56%
18.57%
21.25%
16.37%
12.76%
7.09%
1.91%
0.75%
Net Income Growth (1Y)
31.47%
88.53%
65.60%
111.47%
57.67%
-39.11%
-44.09%
-60.77%
-52.47%
2.52%
10.69%
21.34%
EPS Growth (1Y)
30.98%
88.18%
65.30%
111.08%
57.08%
-39.34%
-44.30%
-60.92%
-52.65%
3.09%
10.69%
21.34%
Valuation Metrics
P/E TTM
24.18
22.51
21.21
22.03
27.19
32.67
38.74
50.42
37.82
21.26
17.47
13.58
P/B TTM
20.52
20.05
15.45
19.63
25.99
22.73
21.77
26.63
28.34
22.91
17.27
15.97
P/S TTM
5.07
4.72
4.13
4.18
4.73
4.00
5.04
5.10
4.82
5.06
4.93
4.08
Market Cap
188.57B
173.57B
148.59B
145.83B
161.30B
133.61B
163.86B
157.80B
142.31B
142.78B
132.19B
108.33B
Enterprise Value
233.86B
219.05B
193.73B
194.01B
209.87B
181.74B
215.25B
211.14B
196.63B
196.45B
157.92B
135.62B
Calculated Values
Free Cash Flow TTM
8.60B
8.10B
11.54B
10.61B
10.92B
10.39B
6.28B
5.48B
7.10B
7.36B
9.38B
9.69B
Net Debt
45.29B
45.48B
45.14B
48.18B
48.57B
48.13B
51.39B
53.34B
54.31B
53.67B
25.73B
27.30B
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of data

Insider Transactions

2026-05-04Sale
Owner: Grygiel, Nancy A.
Title: SVP & CCO
Shares: 1,237
Price/Share: $323.73
Value: $400,454.01
Shares Owned: 7,009
Relationship: Officer
Ownership: Direct
2026-02-26Sale
Owner: Santos, Esteban
Title: EVP, Operations
Shares: 54,792
Price/Share: $379.12
Value: $20,772,743.04
Shares Owned: 76,618
Relationship: Officer
Ownership: Direct
2026-02-19Sale
Owner: Busch, Matthew C.
Title: VP, Finance & CAO
Shares: 1,000
Price/Share: $375.79
Value: $375,790.00
Shares Owned: 3,423
Relationship: Officer
Ownership: Direct
2025-11-20Sale
Owner: Grygiel, Nancy A.
Title: SVP & CCO
Shares: 3,139
Price/Share: $337.26
Value: $1,058,659.14
Shares Owned: 7,225
Relationship: Officer
Ownership: Direct
2025-11-12Sale
Owner: Gordon, Murdo
Title: EVP, Global Commercial Ops
Shares: 6,879
Price/Share: $336.83
Value: $2,317,053.57
Shares Owned: 41,923
Relationship: Officer
Ownership: Direct

Subscribe to unlock 17+ years of data

Institutional Ownership

No data available for chart
2026-03-31
76.02%
Inst. Shares: 410,506,543
Shares Outstanding: 540,000,000
2025-12-31
78.70%
Inst. Shares: 423,423,904
Shares Outstanding: 538,000,000
2025-09-30
76.05%
Inst. Shares: 409,139,628
Shares Outstanding: 538,000,000
2025-06-30
77.08%
Inst. Shares: 414,673,489
Shares Outstanding: 538,000,000
2025-03-31
75.28%
Inst. Shares: 405,021,304
Shares Outstanding: 538,000,000

AMGEN INC (AMGN) — SEC Financial Statements & Analysis

AMGEN INC (AMGN) is a biological products, (no diagnostic substances) company, incorporated in DE. AMGEN INC trades on AMGN: Nasdaq as: AMGN. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), AMGEN INC reported a 9.07% year-over-year revenue growth, a Gross Profit Margin of 68.26% (TTM), a Debt-to-Equity ratio of 2.72x, a Price-to-Sales (P/S) ratio of 5.07x (TTM), a Price-to-Book (P/B) ratio of 20.52 (TTM), at a market cap of $188.57B. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y
9.07%
Gross Profit Margin TTM
68.26%
Debt To Equity
2.72x
P/S TTM
5.07x
P/B TTM
20.52
Market Cap
$188.57B

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is AMGEN INC in?

AMGEN INC (AMGN) operates in the Biological Products, (No Diagnostic Substances) industry.

What is AMGN's market cap?

AMGEN INC (AMGN) has a market capitalization of $188.57B as of 2026-03-31.

What is AMGN's P/E ratio?

AMGEN INC (AMGN)'s trailing twelve month P/E ratio is 24.18x as of 2026-03-31.

What exchange does AMGN trade on?

AMGEN INC (AMGN) trades on the AMGN: Nasdaq.

Where is AMGEN INC incorporated?

AMGEN INC is incorporated in DE.

Research Faster.
Invest Smarter.

AMGEN INC (AMGN) financial data sourced directly from SEC EDGAR filings — including the latest 10-K annual report, 10-Q quarterly filings, insider transactions (SEC Form 4), institutional ownership (SEC Form 13F), Earning Marker Reaction Heat Map and 50+ calculated financial metrics like Price to Earnings Ratio (P/E), Return on Equity (ROE), Debt to Equity (D/E), Free Cash Flow Per Share (FCF/S), and Return on Invested Capital (ROIC). Unlike platforms that rely on third-party data aggregators, GeminIQ parses raw SEC filings directly — delivering institutional-grade accuracy at a fraction of the cost of Bloomberg Terminal or S&P Capital IQ.